If you or a loved one has been taking Reglan (metoclopramide) and noticed involuntary muscle movements, you may be concerned about tardive dyskinesia. Ongoing pharmacovigilance and updated labeling continue to refine our understanding of this risk. This page reviews current research and monitoring recommendations for Reglan users in Colorado.
Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly prescribed for conditions such as diabetic gastroparesis and symptomatic gastroesophageal reflux. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. This narrative examines the clinical presentation, pharmacological mechanisms, and settlement-related considerations for affected patients, based on available evidence. Tardive dyskinesia is characterized by involuntary, repetitive movements, often involving the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after discontinuation of the triggering medication. The condition is diagnosed based on clinical presentation, with a history of exposure to dopamine receptor blocking agents being a key factor. Metoclopramide, including Reglan, can cause TD, and the risk increases with longer treatment duration and higher cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In some cases, TD can develop after a single dose, particularly in patients with underlying risk factors, as reported in a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/).
The pharmacological mechanism linking Reglan to TD involves its action as a dopamine D2-receptor antagonist. By blocking dopamine receptors in the brain, metoclopramide can lead to extrapyramidal side effects, including TD. This mechanism is similar to that of antipsychotic medications, and the incidence of TD with antiemetics like metoclopramide is likely comparable to that seen with atypical antipsychotics (https://pubmed.ncbi.nlm.nih.gov/29433808/). The condition may also be masked by continued use of the drug, as metoclopramide can suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Risk factors for developing TD include prolonged exposure to metoclopramide, higher cumulative doses, and individual patient susceptibility. The FDA-approved labeling for Reglan includes a boxed warning emphasizing that the risk of TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, treatment should not exceed 12 weeks, and if longer use is unavoidable, routine monitoring for TD symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Similarly, for symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Despite these warnings, many patients have been prescribed Reglan for extended periods, leading to harm. The adequacy of warnings regarding Reglan and TD is a critical issue in settlement considerations. The boxed warning clearly states that metoclopramide can cause TD and that the drug is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, some patients and healthcare providers may not have been fully informed of these risks, particularly in cases where the drug was used off-label or for longer than recommended. Settlement-related considerations for affected patients often involve demonstrating that the prescribing physician failed to adequately warn about the risk of TD, or that the patient was not monitored appropriately. The timeline between exposure and documented harm is also important; TD can develop months or years after starting Reglan, and symptoms may persist even after discontinuation. For patients who develop TD, treatment options include VMAT2 inhibitors, which have been FDA-approved for this condition. These medications, such as tetrabenazine and its derivatives, work by modulating dopamine release in the brain (https://pubmed.ncbi.nlm.nih.gov/29433808/). However, not all patients respond to these treatments, and the condition can be disabling.
In summary, Reglan use is associated with a significant risk of tardive dyskinesia, a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher doses, and even single doses can trigger TD in susceptible individuals. Adequate warnings are provided in the drug labeling, but settlement cases often hinge on whether these warnings were effectively communicated and whether the drug was used appropriately. Patients who have developed TD after Reglan exposure may be eligible for compensation, particularly if they can demonstrate that the prescribing physician failed to follow recommended guidelines or adequately monitor for symptoms. An independent eligibility review can help determine if a patient meets the criteria for a Reglan TD lawsuit settlement.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements, often involving the face, tongue, trunk, or extremities. Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause TD, especially with prolonged use or high doses. The risk is highlighted in a boxed warning on the drug label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Settlement criteria typically require documented exposure to Reglan, a confirmed diagnosis of tardive dyskinesia, and evidence that the prescribing physician failed to adequately warn about the risk or monitor for symptoms. The timeline between exposure and diagnosis is also important. Patients may be eligible for an independent eligibility review.
Tardive dyskinesia can develop months or even years after starting Reglan. The risk increases with longer treatment duration and higher cumulative doses. In some cases, TD can occur after a single dose, particularly in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/).
Yes, VMAT2 inhibitors such as tetrabenazine and its derivatives are FDA-approved for treating tardive dyskinesia. These medications modulate dopamine release in the brain (https://pubmed.ncbi.nlm.nih.gov/29433808/). However, not all patients respond to treatment, and the condition can be disabling.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.